Symbio Announces Phase I Clinical Unit
Symbio LLC, a full service contract research organization, has announced the opening of a new Phase I Clinical Unit in Michigan City, Indiana.
Port Jefferson, NY – Symbio LLC, a full service contract research organization, has announced the opening of a new Phase I Clinical Unit. Since 2002, Symbio has provided services to pharmaceutical, generic and medical device companies that have resulted in many successful clinical trials. Services provided by Symbio include: clinical trial management, biometrics, strategic consulting, product development and topical formulation development. With the addition of the Phase I Unit, a key component to the complete clinical development process, Symbio now has the ability to provide development from Phase I through Phase IV.
In collaboration with Saint Anthony Memorial Hospital in Michigan City, Indiana, the Phase I Unit is a 62 bed capacity facility and is located within the confines of Saint Anthony Memorial Hospital. The hospital provides an entire floor devoted to the conduct of Phase I studies, ensuring the highest quality medical care and safety standards.
Symbio has long-standing, special expertise working with the generic drug industry. The Symbio Phase I Clinical Team is set up to prepare and execute clinical plans to support FDA approval of generic products.
Symbio’s Phase I Unit at Saint Anthony Memorial Hospital is centrally located in northwest Indiana, between the Illinois and Michigan state borders.
Just 45 minutes from downtown Chicago, diverse populations of healthy participants are easily accessible including eight local colleges/universities and technical schools.
For further information contact: Edward Drower, Director of Phase I Clinical Operations
Phone: 219-861-8817, Email: edrower@symbioresearch.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
